In clinical settings, Perjeta and Herceptin targeting HER2 have been widely used in HER2 overexpressed breast cancer and gastric adenocarcinoma and have achieved excellent clinical results [27]. This evidence concerns the gene ERBB2 and gastric adenocarcinoma.